¼¼¹Ì³ª/Çà»ç

> Á¤º¸¼¾ÅÍ > ¼¼¹Ì³ª/Çà»ç

Á¦¸ñ 2017³â 10¿ù 12ÀÏ »ý¹°Á¤º¸ÇÐ ¼¼¹Ì³ª
ÀÛ¼ºÀÚ °ü¸®ÀÚ ÀÛ¼ºÀÏ 2017-10-10

¼­¿ï´ëÇб³ »ý¹°Á¤º¸¿¬±¸¼Ò¿Í »ý¹°Á¤º¸ÇÐ Çùµ¿°úÁ¤ °øµ¿ ÁÖÃÖ·Î ¼¼¹Ì³ª¸¦ ¾Æ·¡¿Í °°ÀÌ ¿­°íÀÚ ÇÏ¿À´Ï, ¸¹Àº Âü¿© ¹Ù¶ø´Ï´Ù.

¡¡

ÀϽÃ: 2017³â 10¿ù 12ÀÏ ¸ñ¿äÀÏ ¿ÀÀü 11½Ã

¿¬»ç: ÀÌ´ëÈ£ (°¡Ãµ´ë ±æº´¿ø ³»ºÐºñ´ë»ç³»°ú)

Àå¼Ò: ¼­¿ï´ëÇб³ 25µ¿ 411È£

¡¡

Title

Clinical perspectives of metagenome researches on metabolic diseases and complications


Abstract

The gut microbiota consists of over 10 trillion microbial cells, which carry greater than 100-fold more genes than the human genome, and is a primary source of thousands of small molecules and other bioactive compounds. The human gut microbiota also contains about 1000 different bacterial species with defined functions. Importantly, gut microbes communicate with the human host in either a symbiotic or deleterious fashion, keeping the optimal state of host health, but also being implicated in the pathogenesis of numerous metabolic diseases, such as obesity, diabetes, chronic kidney disease and cardiovascular diseases and cancers. Previous studies have shown a link between the gut microbiota and human metabolic health, with transferability of insulin resistance phenotypes through faecal microbiome transplants. These effects may partly be mediated through the microbial metabolites. Serum levels of amino acids, most consistently the branched-chain amino acids (BCAAs), triacylglycerols with low carbon number and double bonds, as well as specific membrane phospholipids, have previously been associated with insulin resistance and risk of metabolic diseases and cardiovascular complications. In light of the critical role of a molecular dialog in maintaining a productive mutualism, the community of researchers studying the symbiosis between humans and their microbiota has begun moving from a focus on ¡®who¡¯s there¡¯ to ¡®what are they doing¡¯. Thus, advances in metagenomics and metabolomics have led to the discovery of thousands of microbe-derived small molecules as well as the genes associated with their production. We have ~150 subjects¡¯ metagenome data analyzed in serum and urine samples from normal control, patients with type 2 diabetes mellitus (T2DM), and T2DM patients with progressive diabetic kidney disease (DKD). These data may be useful for finding a metagenomics marker for rapidly progressive DKD and for understanding pathophysiological association between metabolic diseases/complications and microbiota.


Education

Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ Çлç, ¼®»ç, ÀÇÇйڻç


Experience

1991-2000 Àü³²´ëÇб³º´¿ø ³»°ú Àü°øÀÇ, ³»ºÐºñ´ë»ç³»°ú Clinical fellow

2003-2013 Á¦ÁÖÀÇ´ë ±³¼ö

2007-2009 ¹Ì±¹ÇϹöµå ÀÇ´ë ¿¬¼ö(Visiting Scholar)

2013-2016 ¿ø±¤ÀÇ´ë ±³¼ö

2016~ÇöÀç °¡Ãµ´ë ±æº´¿ø ³»ºÐºñ´ë»ç³»°ú ±³¼ö

¿¬±¸Á߽ɺ´¿ø À°¼º R&D »ç¾÷ 5¼¼ºÎ Ã¥ÀÓ

´ëÇÑ´ç´¢º´ÇÐȸ ¿¬±¸ÀÌ»ç

¡¡

¼­¿ï´ëÇб³ »ý¹°Á¤º¸¿¬±¸¼Ò

»ý¹°Á¤º¸ÇÐ Çùµ¿°úÁ¤ °øµ¿ÁÖÃÖ